RAC 0.97% $1.54 race oncology ltd

Ann: Race investor briefing & updated presentation, page-59

  1. 2,679 Posts.
    lightbulb Created with Sketch. 10298
    Normally people who participate in a Phase I trial have reached the end of the road in regards other treatment options so this is not an issue. More of an issue is the patients are pretty sick and beat up, but given we are aiming to test a very low dose of Bisantrene this hopefully will not be too much of an issue.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.